Wed May 25, 2022 – 10:49 pm EDT
(LifeSiteNews) — Pfizer says they plan to submit data to the Food and Drug Administration this week to get their three-dose COVID vaccine regimen approved for use in children aged 6 months to 5 years.
After running a trial in which 1,678 children were injected with three one-tenth strength doses of the experimental mRNA COVID gene-therapy jabs, Pfizer says they are now ready to seek FDA approval. According to the company, the shots were “well tolerated” in the youngsters as most side effects were “mild or moderate.”
“Our COVID-19 vaccine has been studied in thousands of children and adolescents, and we are pleased that our formulation for the youngest children, which we carefully selected to be one-tenth of the dose strength for adults, was well tolerated and produced a strong immune response,” Albert Bourla, the chairman and CEO at Pfizer, said in a statement.
“These topline safety, immunogenicity and efficacy data are encouraging, and we look forward to soon completing our submissions to regulators globally with the hope of making this vaccine available to younger children as quickly as possible, subject to regulatory authorization,” Bourla added.
As reported by LifeSiteNews, despite
The remainder of this article is available in its entirety at LifeSite News
The views expressed in this news alert by the author do not directly represent that of The Official Street Preachers or its editors
